IKENA ONCOLOGY
Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing five programs that include four product candidates in either clinical development or IND-enabling studies: IK-930, a TEAD inhibitor targeting the Hippo signaling pathway; an ERK5 inhibitor program targeting the KRAS signaling pathway; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme; and IK-007, an EP4 receptor antagonist. Ikena has entered into a global strategic collaboration with Bristol-Myers Squibb Company for its IK-175 and IK-412 programs.
IKENA ONCOLOGY
Industry:
Biotechnology Health Care Therapeutics
Founded:
2016-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.ikenaoncology.com
Total Employee:
11+
Status:
Active
Contact:
1-857-273-8343
Email Addresses:
[email protected]
Total Funding:
169 M USD
Technology used in webpage:
SPF Wordpress Plugins Nginx Microsoft Exchange Online Office 365 Mail GoDaddy DNS Mimecast
Similar Organizations
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Bristol Myers Squibb
Bristol Myers Squibb investment in Series B - Ikena Oncology
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Series B - Ikena Oncology
Invus
Invus investment in Series B - Ikena Oncology
Farallon Capital Management
Farallon Capital Management investment in Series B - Ikena Oncology
Surveyor Capital
Surveyor Capital investment in Series B - Ikena Oncology
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series B - Ikena Oncology
OrbiMed
OrbiMed investment in Series B - Ikena Oncology
HealthCor Partners
HealthCor Partners investment in Series B - Ikena Oncology
Logos Capital
Logos Capital investment in Series B - Ikena Oncology
BVF Partners
BVF Partners investment in Series B - Ikena Oncology
Key Employee Changes
| Date | New article |
|---|---|
| 2022-04-13 | Ikena Appoints Jotin Marango, M.D., Ph.D., as Chief Financial Officer and Head of Corporate Development |
Official Site Inspections
http://www.ikenaoncology.com Semrush global rank: 352.8 K Semrush visits lastest month: 167.49 K
- Host name: 66-135-14-109.constant.com
- IP address: 66.135.14.109
- Location: Salt Lake City United States
- Latitude: 40.6487
- Longitude: -111.9682
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84129
More informations about "Ikena Oncology"
About Us - Ikena Oncology
About Us At Ikena®, we strive to understand what drives every patient’s cancer. Each member of our team is committed to this goal and offers their unique se ...See details»
Ikena Oncology | Investors
Corporate Profile. Ikena Oncology® develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance.See details»
Ikena Oncology Outlines Key Priorities and Provides Corporate
Jan 18, 2024 With approximately $175 million in cash and cash equivalents as of December 31, 2023 (unaudited), and as a result of the organization changes the Company’s runway is …See details»
Ikena Oncology - LinkedIn
Ikena Oncology | 9,812 followers on LinkedIn. Patient-directed oncology therapies across pathways relevant in tumor and immune cells | Ikena is a targeted oncology company focused …See details»
Ikena Oncology | Ikena Oncology Reports Fourth Quarter and Full …
Mar 14, 2023 The Company also provided an update across the organization and pipeline. “We’re thrilled to report the meaningful progress made in 2022 across our entire pipeline. We …See details»
Ikena Oncology Outlines Key Priorities and Provides Corporate …
Jan 18, 2024 IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024 IK-595 first cohort treated and cleared safety evaluation window …See details»
Ikena Oncology - Crunchbase Company Profile & Funding
Organization. Ikena Oncology . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Contact Email …See details»
Ikena Oncology to Participate in TD Cowen 44th Annual Health …
BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer …See details»
Ikena Oncology | Ikena Appoints Jotin Marango, M.D., Ph.D., as …
Apr 13, 2022 Dr. Marango brings years of valued experience in oncology biopharma business, finance, and corporate relations & development. BOSTON, April 13, 2022 (GLOBE …See details»
UPDATE – Ikena Oncology Announces Strategic Update - Yahoo …
May 28, 2024 Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first …See details»
Mark Manfredi, Ph.D. | Ikena Oncology
During his time at Takeda, the Oncology organization advanced eight novel mechanisms into the clinic, including ixazomib, which was recently approved by the FDA for the treatment of …See details»
Careers - Ikena Oncology
We have team members that work within a true hybrid setting and others who work in our state-of-the art, newly designed labs in Boston. All Ikenians are committed to being culture champions, …See details»
Ikena Oncology Outlines Key Priorities and Provides
Jan 18, 2024 With approximately $175 million in cash and cash equivalents as of December 31, 2023 (unaudited), and as a result of the organization changes the Company’s runway is …See details»
Ikena Oncology Closes $120 Million Series B Financing Led by …
Jan 5, 2021 For more information, visit www.ikenaoncology.com, or follow us on Twitter and LinkedIn. Contacts Investor: Sam Martin Argot Partners 646-233-4302 …See details»
Ikena Oncology Reports First Quarter 2024 Financial Results and ...
May 13, 2024 Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in …See details»
Ikena Oncology Outlines Key Priorities and Provides ... - BioSpace
Jan 18, 2024 With the advancement of IK-930 and IK-595, the Company has made the strategic decision to reallocate resources from the discovery organization to the clinical programs This …See details»
Ikena Oncology Appoints Owen Hughes as Board Chair
To learn more, visit www.ikenaoncology.com or follow us on Twitter and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the …See details»
Ikena Oncology, Inc. (IKNA) Stock Price, Quote & News - Stock …
6 days ago Website https://ikenaoncology.com. Full Company Profile. Financial Performance. In 2023, Ikena Oncology's revenue was $9.16 million, a decrease of -41.35% compared to the …See details»
Pipeline - Ikena Oncology
Cookie Duration Description; _ga: 2 years: The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's …See details»